logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

I-Cordis Receives Sbir Phase Ii Funding To Develop Treatment For Heart Failure With Preserved Ejection Fraction

I-Cordis Receives Sbir Phase Ii Funding To Develop Treatment For Heart Failure With Preserved Ejection Fraction

09/01/22, 12:20 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgst. louis
i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF).

Company Info

Company
i-Cordis
Location
st. louis, missouri, united states
Additional Info
i-Cordis' mission is to bring together physician-scientists, heart failure experts, basic scientists and drug development experts to develop innovative, safe and effective immuno-modulatory molecules to bring relief to patients with heart failure with preserved ejection fraction.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.

Related people

LH

DH

Sign up to get related executive contact information